NEW YORK, March 30, 2016 -- AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq:AMCX) today announced the closing of its previously announced tender offer to purchase for cash (the “Tender Offer”) any and all of its outstanding 7.75% Senior Notes due 2021 (the “Notes”). The Tender Offer expired at 5:00 p.m., New York City time, on March 29, 2016 (the “Expiration Date”). At the Expiration Date, valid tenders had been received with respect to approximately $654 million of the $700 million aggregate principal amount of the 2021 Notes outstanding.
The Company has accepted for payment all 2021 Notes validly tendered prior to the Expiration Date pursuant to the Tender Offer. On March 30, 2016, such tendering holders will receive the purchase price in the amount of $1,058.57 for each $1,000 principal amount of 2021 Notes tendered, plus accrued and unpaid interest to, but not including, the date hereof. In addition, the Company will accept any additional 2021 Notes properly tendered by means of the guaranteed delivery procedures provided.
Dedicated to producing quality programming and content for more than 30 years, AMC Networks Inc. owns and operates several of the most popular and award-winning brands in cable television. AMC, IFC, SundanceTV, WE tv, and IFC Films produce and deliver distinctive, compelling and culturally relevant content that engages audiences across multiple platforms. The company also operates BBC America through a joint venture with BBC Worldwide. In addition, the company operates AMC Networks International, its global division.
This press release may contain statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that any such forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties, and that actual results or developments may differ materially from those in the forward-looking statements as a result of various factors, including financial community and rating agency perceptions of the company and its business, operations, financial condition and the industries in which it operates and the factors described in the company’s filings with the Securities and Exchange Commission, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained therein. The company disclaims any obligation to update any forward-looking statements contained herein.
Contacts: Seth Zaslow Investor Relations 646-273-3766 [email protected] Georgia Juvelis Corporate Communications 917-542-6390 [email protected]


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Italy Fines Apple €98.6 Million Over App Store Dominance
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



